An empirical study of large, human biobanks: intellectual property policies and financial conditions for access

Abstract

Biobanks are repositories that collect, store and distribute large quantities of biological samples and associated data (collectively called biobank `material'). Although biobanks have different modes of operation, all face a variety of similar challenges. Some of these challenges, such as donor consent and privacy, have been rigorously debated, but comparatively less attention has been paid to biobanks' intellectual property (IP) practices. IP rights (particularly patents) are integral to the translation of research into clinically relevant outcomes and, therefore, are key features in the business models of many biobanks. As a foundation for such research, commentators have identified five IP clauses of interest: (i) non-obstruction clauses; (ii) march-in clauses; (iii) grant-back clauses; (iv) return-of-results clauses and (v) reach-through clauses (also commonly called `reach-through rights'). In the limited literature that discusses the five clauses, commentators have largely debated their advantages and disadvantages in the abstract. The IP terms that biobanks actually use have not been empirically examined, apart from some small case studies. In particular, no industry-wide evidence exists on three points of biobanks' IP practice: (i) if and how biobanks implement these five types of IP clauses, (ii) whether any norms or standards have emerged, and (iii) whether the norms and standards align with commentators' recommendations for using the five IP clauses. To address these three gaps, the authors conducted a systematic, global survey of the IP clauses used by large, human biobanks. The results indicate that biobanks draft bespoke policies to meet their own needs, and probably do so without knowledge of the gamut of IP terms available. This study also revealed that, in general, biobanks are using IP terms differently from the advice of the commentators. On reviewing the differences, we encourage the use of march-in and grant-back clauses, discourage biobanks from using redundant non-obstruction clauses, and call for more research on return-of-results clauses. We also encourage the use of reach-through clauses to claim royalties (not IP), but only in limited circumstances; for example, where user access fees do not cover a biobanks' operational costs.

Patient data for commercial companies? An ethical framework for sharing patients’ data with for-profit companies for research

“…While companies have a legitimate right to pursue and realise profits, in the case of ReuseForPro particular restrictions to this right are justified if necessary to safeguard social benefit of ReuseForPro. 41…”

International Biospecimen Sourcing Platform: A Key Player in Advancing Health Research and Drug Discovery

“…Another significant hurdle is ensuring alignment of informed consent procedures with the regulations of multiple jurisdictions, necessitating clear and legally compliant consent documentation for each participating country 45,46 . Intellectual property rights present a distinct legal challenge, involving the determination of ownership for biospecimen and the associated data, potentially leading to legal disputes 47,48 . Additionally, complying with the legal requirements of various international and local research governance frameworks proves to be challenging 49,50 .…”

Biobancos e sua aplicabilidade em ensino e pesquisa: revisão de literatura

“…Brazilian Journal of Health Review, Curitiba, v. 6, n. 1, p.3467-3480, jan./feb., 2023 semelhantes (JORDAN, LIDDICOAT & LIDDEL, 2021). Há uma variedade de procedimentos operacionais padrão ou protocolos de melhores práticas para biobancos, e a determinação de qual usar geralmente depende das necessidades específicas da clínica ou do estudo que está sendo realizado (HARATI et al, 2019).…”